- Home
- MBIO vs LYRA Comparison
MBIO vs LYRA Comparison
Compare MBIO & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- LYRA
- Stock Information
- Founded
- MBIO 2015
- LYRA 2005
- Country
- MBIO United States
- LYRA United States
- Employees
- MBIO N/A
- LYRA N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- MBIO Health Care
- LYRA Health Care
- Exchange
- MBIO Nasdaq
- LYRA Nasdaq
- Market Cap
- MBIO 7.3M
- LYRA 6.1M
- IPO Year
- MBIO N/A
- LYRA 2020
- Fundamental
- Price
- MBIO $1.22
- LYRA $0.11
- Analyst Decision
- MBIO Strong Buy
- LYRA Hold
- Analyst Count
- MBIO 1
- LYRA 4
- Target Price
- MBIO $100.00
- LYRA $1.25
- AVG Volume (30 Days)
- MBIO 1.0M
- LYRA 1.8M
- Earning Date
- MBIO 05-14-2025
- LYRA 05-06-2025
- Dividend Yield
- MBIO N/A
- LYRA N/A
- EPS Growth
- MBIO N/A
- LYRA N/A
- EPS
- MBIO N/A
- LYRA N/A
- Revenue
- MBIO N/A
- LYRA $1,534,000.00
- Revenue This Year
- MBIO N/A
- LYRA N/A
- Revenue Next Year
- MBIO N/A
- LYRA $237.15
- P/E Ratio
- MBIO N/A
- LYRA N/A
- Revenue Growth
- MBIO N/A
- LYRA N/A
- 52 Week Low
- MBIO $1.13
- LYRA $0.08
- 52 Week High
- MBIO $65.00
- LYRA $5.65
- Technical
- Relative Strength Index (RSI)
- MBIO 35.82
- LYRA 42.33
- Support Level
- MBIO $1.13
- LYRA $0.08
- Resistance Level
- MBIO $1.38
- LYRA $0.10
- Average True Range (ATR)
- MBIO 0.12
- LYRA 0.01
- MACD
- MBIO 0.04
- LYRA 0.00
- Stochastic Oscillator
- MBIO 33.33
- LYRA 62.16
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.